|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPSB1 |
Gene summary for SPSB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPSB1 | Gene ID | 80176 |
| Gene name | splA/ryanodine receptor domain and SOCS box containing 1 | |
| Gene Alias | SSB-1 | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R4G8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80176 | SPSB1 | LZE4T | Human | Esophagus | ESCC | 4.50e-04 | 4.99e-02 | 0.0811 |
| 80176 | SPSB1 | LZE7T | Human | Esophagus | ESCC | 2.28e-02 | -3.55e-02 | 0.0667 |
| 80176 | SPSB1 | LZE8T | Human | Esophagus | ESCC | 3.59e-05 | -4.84e-02 | 0.067 |
| 80176 | SPSB1 | LZE20T | Human | Esophagus | ESCC | 6.50e-04 | -1.07e-01 | 0.0662 |
| 80176 | SPSB1 | LZE24T | Human | Esophagus | ESCC | 2.86e-15 | 6.23e-01 | 0.0596 |
| 80176 | SPSB1 | P1T-E | Human | Esophagus | ESCC | 1.69e-03 | 1.33e-01 | 0.0875 |
| 80176 | SPSB1 | P2T-E | Human | Esophagus | ESCC | 1.66e-09 | 3.61e-01 | 0.1177 |
| 80176 | SPSB1 | P4T-E | Human | Esophagus | ESCC | 6.02e-13 | 2.95e-01 | 0.1323 |
| 80176 | SPSB1 | P5T-E | Human | Esophagus | ESCC | 3.55e-13 | 2.00e-01 | 0.1327 |
| 80176 | SPSB1 | P8T-E | Human | Esophagus | ESCC | 1.26e-17 | 5.03e-02 | 0.0889 |
| 80176 | SPSB1 | P9T-E | Human | Esophagus | ESCC | 2.75e-13 | 4.39e-01 | 0.1131 |
| 80176 | SPSB1 | P10T-E | Human | Esophagus | ESCC | 8.05e-13 | 7.41e-02 | 0.116 |
| 80176 | SPSB1 | P11T-E | Human | Esophagus | ESCC | 8.49e-09 | 6.16e-01 | 0.1426 |
| 80176 | SPSB1 | P12T-E | Human | Esophagus | ESCC | 1.12e-11 | 2.99e-01 | 0.1122 |
| 80176 | SPSB1 | P15T-E | Human | Esophagus | ESCC | 6.56e-23 | 6.24e-01 | 0.1149 |
| 80176 | SPSB1 | P16T-E | Human | Esophagus | ESCC | 1.36e-09 | -1.06e-01 | 0.1153 |
| 80176 | SPSB1 | P17T-E | Human | Esophagus | ESCC | 6.94e-04 | 1.38e-01 | 0.1278 |
| 80176 | SPSB1 | P20T-E | Human | Esophagus | ESCC | 1.43e-10 | 2.74e-01 | 0.1124 |
| 80176 | SPSB1 | P21T-E | Human | Esophagus | ESCC | 8.72e-23 | 2.62e-01 | 0.1617 |
| 80176 | SPSB1 | P22T-E | Human | Esophagus | ESCC | 8.66e-19 | 1.96e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:00431617 | Liver | NAFLD | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/1882 | 412/18723 | 3.00e-13 | 1.75e-10 | 91 |
| GO:00104987 | Liver | NAFLD | proteasomal protein catabolic process | 101/1882 | 490/18723 | 1.35e-12 | 6.09e-10 | 101 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
| GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
| GO:0010498110 | Oral cavity | LP | proteasomal protein catabolic process | 224/4623 | 490/18723 | 9.57e-25 | 4.00e-22 | 224 |
| GO:0043161110 | Oral cavity | LP | proteasome-mediated ubiquitin-dependent protein catabolic process | 190/4623 | 412/18723 | 1.08e-21 | 2.93e-19 | 190 |
| GO:001049831 | Oral cavity | NEOLP | proteasomal protein catabolic process | 103/2005 | 490/18723 | 1.08e-11 | 1.65e-09 | 103 |
| GO:004316131 | Oral cavity | NEOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 89/2005 | 412/18723 | 6.27e-11 | 7.44e-09 | 89 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPSB1 | SNV | Missense_Mutation | rs767731224 | c.442N>T | p.Arg148Trp | p.R148W | Q96BD6 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| SPSB1 | SNV | Missense_Mutation | c.207N>T | p.Glu69Asp | p.E69D | Q96BD6 | protein_coding | tolerated(0.63) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SPSB1 | SNV | Missense_Mutation | c.623A>G | p.Lys208Arg | p.K208R | Q96BD6 | protein_coding | tolerated(0.17) | benign(0.018) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SPSB1 | SNV | Missense_Mutation | c.585N>T | p.Gln195His | p.Q195H | Q96BD6 | protein_coding | tolerated(0.07) | benign(0.03) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| SPSB1 | deletion | Frame_Shift_Del | c.365delN | p.Leu124CysfsTer56 | p.L124Cfs*56 | Q96BD6 | protein_coding | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| SPSB1 | deletion | Frame_Shift_Del | c.365delN | p.Leu124CysfsTer56 | p.L124Cfs*56 | Q96BD6 | protein_coding | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |||
| SPSB1 | SNV | Missense_Mutation | novel | c.718T>G | p.Leu240Val | p.L240V | Q96BD6 | protein_coding | deleterious(0.02) | possibly_damaging(0.83) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| SPSB1 | SNV | Missense_Mutation | novel | c.386N>G | p.Tyr129Cys | p.Y129C | Q96BD6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPSB1 | SNV | Missense_Mutation | c.337N>A | p.Ala113Thr | p.A113T | Q96BD6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BS-A0UL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SPSB1 | SNV | Missense_Mutation | rs752688288 | c.668G>A | p.Arg223Gln | p.R223Q | Q96BD6 | protein_coding | tolerated(0.19) | benign(0.073) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |